The Impact of Smoking on Selected Serum Adipokines in Patients with Psoriasis

Czech version

Authors: S. Vachatová ¹; K. Ettler ¹; L. Borská ²; J. Krejsek ³; C. Andrýs ³; E. Čermáková ⁴; V. Řeháček ⁵; Z. Fiala ⁶
Authors‘ workplace: Klinika nemocí kožních a pohlavních, Fakultní nemocnice Hradec Králové, Univerzita Karlova, Lékařská fakulta v Hradci Králové přednosta doc. MUDr. Miloslav Salavec, CSc. ¹; Ústav patologické fyziologie, Univerzita Karlova, Lékařská fakulta v Hradci Králové přednosta prof. MUDr. Miroslav Kuba, CSc. ²; Ústav klinické imunologie a alergologie, Fakultní nemocnice Hradec Králové, Univerzita Karlova, Lékařská fakulta v Hradci Králové přednosta prof. RNDr. Jan Krejsek, CSc. ³; Ústav lékařské biofyziky, Univerzita Karlova, Lékařská fakulta v Hradci Králové přednosta doc. Ing. Josef Hanuš, CSc. ⁴; Transfuzní oddělení Fakultní nemocnice Hradec Králové primář MUDr. Vít Řeháček ⁵; Ústav hygieny a preventivního lékařství, Univerzita Karlova, Lékařská fakulta v Hradci Králové přednosta prof. Ing. Zdeněk Fiala, CSc. ⁶
Published in: Čes-slov Derm, 92, 2017, No. 6, p. 264-274
Category: Pharmacologyand Therapy, Clinical Trials

Overview

Psoriasis is a chronic relapsing inflammatory disease affecting 2–3% of European population. The components of metabolic syndrome (MetS) include obesity, dylipidemia, high blood pressure and insulin resistence. MetS can increase the risk of cardiovascular disease and diabetes mellitus type II (DM2T) which prevalence is 25–30% in developed countries. Smoking is closely related to MetS: smokers are at higher risk of MetS. Patients with psoriasis are more likely to be smokers and have higher risk of developing MetS. Link between psoriasis and MetS can be explained by subclinical inflammation and elevation of adipokines levels, present in both diseases. Smoking activates inflammatory processes via oxidative stress that contributes to chronicity of psoriasis. The aim of this study was to compare inflammatory markers – C-reactive protein (CRP), leptin, adiponectin, resistin and lipoprotein associated phospholipase A2 (LpPLA2) as well as the factors of MetS between patients with psoriasis (PP) and the control group (CG) witht respect to positivity of MetS and smoking history. PP have a statistically non-significant higher tendency to smoke. In the PP group 40.5% of patients smoked and in the control group only 30.8% of individuals. Next, significantly higher psoriasis area and severity index (PASI, p < 0.05) was measured in patients without MetS, who smoked in comparison to non-smoking controls without MetS. This finding confirm a direct link between psoriasis and smoking regardless of the presence of MetS. We detected significantly higher levels of pro-inflammatory markers CRP (p < 0.01) and leptin (p < 0.05) and proatherogenic marker Lp-PLA2 (p < 0.01) in the group of PP non-smokers suffering with MetS in comparsion to non-smoking CG suffering with MetS. Levels of CRP (p = 0.001), Lp-PLA2 (p < 0.001), leptin (p = 0.006) and resistin (p = 0.005) were statistically significantly related to psoriasis. According to our study psoriasis and obesity are related due to significantly higher BMI (p < 0.05) in PP nonsmokers with MetS in comparsion to CG nonsmokers with MetS. In conclusion we can state that psoriasis is an inflammatory state related to obesity regardless of smoking history, but the severity of psoriasis is aggravated by smoking.

Key words:
psoriasis – obesity – metabolic syndrome – smoking – C-reactive protein – lipoprotein associated phospholipase A2 – adiponectin – leptin – resistin

Sources

1. ABUABARA, K., AZFAR, R. S., SHIN, D. B. et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br. J. Dermatol., 2010, 163, 3, p. 586–592.

2. ALBANES, D., JONES, D. Y., MICOZZI, M. S., MATTSON, M. E. Associations between smoking and body weight in the US population: analysis of NHANES II. Am. J. Public. Health, 1987, 77, 4, p. 439–444.

3. ALSUFYANI, M. A., GOLANT, A. K., LEBWOHL, M. Psoriasis and the metabolic syndrome. Dermatol. Ther., 2010, 23, 2, p. 137–143.

4. ARMSTRONG, A. W., ARMSTRONG, E. J., FULLER, E. N. et al. Smoking and pathogenesis of psoriasis. Br. J. Dermatol., 2011, 165, 6, p. 1162–1168.

5. ARMSTRONG, A. W., HARSKAMP, C. T., ARMSTRONG, E. J. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes, 2012, 2. doi:10.1038/nutd.2012.26.

6. BAI, X. J., FAN, L. H., HE, Y. et al. Nicotine may affect the secretion of adipokines leptin, resistin, and visfatin through activation of KATP channel. Nutrition, 2016, 32, 6, p. 645–648.

7. BALCI, A., BALCI, D. D., YONDEN, Z. et al. Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology, 2010, 220, 1, p. 32–37.

8. BARAN, A., FLISIAK, I., JAROSZEWICZ, J., SWIDERSKA, M. Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. J. Dermatolog. Treat., 2015, 26, 2, p. 134–138.

9. BERGMANN, S., SIEKMEIER, R. Influence of smoking and body weight on adipokines in middle aged women. Eur. J. Med. Res., 2009, 14, 4, p. 21–26.

10. BEYGI, S., LAJEVARDI, V., ABEDINI R. C-reactive protein in psoriasis: a review of the literature. J. Eur. Acad. Dermatol. Venereol., 2014, 28, 6, p. 700–711.

11. CAMPANATI, A., GANZETTI, G., GIULIODORI, K. et al. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis. Int. J. Dermatol., 2015, 54, 7, p. 839–845.

12. CANOY, D., WAREHAM, N., LUBEN, R. et al. Cigarette smoking and fat distribution in 21, 828 British men and women: a population-based study. Obes. Res, 2005, 13, 8, p. 1466–1475.

13. CARLSSON, S., MIDTHJELL, K., GRILL, V. et al. Smoking is associated with an increased risk of type 2 diabetes but a decreased risk of autoimmune diabetes in adults: an 11-year follow-up of incidence of diabetes in the Nord-Trøndelag study. Diabetologia, 2004, 47, 11, p. 1953–1956.

14. COBAN, M., TASLI, L., TURGUT, S. et al. Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. Ann. Dermatol., 2016, 28, 1, p. 74–79.

15. COIMBRA, S., OLIVEIRA, H., REIS, F. et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J. Eur. Acad. Dermatol. Venereol., 2010, 24, 7, p. 789–796.

16. CRAIG, W. Y., PALOMAKI, G. E., HADDOW, J. E. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ, 1989, 298, 6676, p. 784–788.

17. FAN, L. H., HE, Y., XU, W. et al. Adiponectin may be a biomarker of early atherosclerosis of smokers and decreased by nicotine through KATP channel in adipocytes. Nutrition, 2015, 31, 7–8, p. 955–958.

18. FORD, E. S., GILES, W. H., DIETZ, W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 2002, 287, 3, p. 356–359.

19. GERDES, S., OSADTSCHY, S., ROSTAMI-YAZDI, M. et al. Leptin, adiponectin, visfatin and retinol-binding protein-4 mediators of comorbidities in patients with psoriasis? Exp. Dermatol., 2012, 21, 1, p. 43–47.

20. GERDES, S., ZAHL, V. A., WEICHENTHAL, M. et al. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology, 2010, 220, 1, p. 38–43.

21. GISONDI, P., GALVAN, A., IDOLAZZI, L., GIROLOMONI, G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front. Med., 2015, 2, 1. doi: 10.3389/fmed.2015.00001.

22. GISONDI, P., TESSARI, G., CONTI, A. et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br. J. Dermatol., 2007, 157, 1, p. 68–73.

23. HAYES, J., KOO, J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol. Ther., 2010, 23, 2, p. 174–180.

24. HERRON, M., HINCKLEY, M., HOFFMAN, M. S. et al. Impact of obesity and smoking on psoriasis presentation and management. Arch. Dermatol., 2005, 141, 12, p. 1527–1534.

25. HOFSTETTER, A., SCHUTZ, Y., JEQUIER, E., WAHREN, J. Increased 24-hour energy expenditure in cigarette smokers. N. Engl. J. Med., 1986, 314, 2, p. 79–82.

26. HOLZER, M., WOLF, P., CURCIC, S. et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J. Lipid Res., 2012, 53, 8, p.1618–1624.

27. HOLZER, M., WOLF, P., INZINGER, M. et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J. Invest. Dermatol., 2014, 134, 3, p. 635–642.

28. HORÁKOVÁ, D., AZEEM, K., DUMBROVSKÁ, L. et al. Epidemiological significance of the metabolic syndrome. Epidemiol. Mikrobiol. Imunol., 2016, 65, 4, p. 215–218.

29. HUANG, H., SHEN, E., TANG, S. et al. Increased serum resistin levels correlate with psoriasis: a meta-analysis. Lipids Health Dis., 2015, 14, p. 44. doi: 10.1186/s12944-015-0039-9.

30. CHIRICOZZI, A., RAIMONDO, A., LEMBO, S. et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adipozity. Expert Rev. Clin. Immunol., 2016, 12, 12, p. 1299–1308.

31. IIDA, M., IIDA, H., DOHI, S. et al. Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo. Stroke, 1998, 29, 8, p. 1656–1665.

32. ISHIZAKA, N., ISHIZAKA, Y., TODA, E. et al. Association between cigarette smoking, metabolic syndrome, and carotid arteriosclerosis in Japanese individuals. Atherosclerosis 2005, 181, p. 381–388.

33. IWASHIMA, Y., KATSUYA, T., ISHIKAWA, I. et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension, 2005, 45, 6, p. 1094–1100.

34. JENSEN, P., SKOV, L. Psoriasis and Obesity. Dermatology, 2016, 232, 6, p. 633–639.

35. JIA, W. P. The Impact of Cigarette Smoking on Metabolic Syndrome. Biomed. Environ. Sci., 2013, 26, 12, p. 947–952.

36. JOHNSTON, A., ARNADOTTIR, S., GUDJONSSON, J. E. et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br. J. Dermatol., 2008, 159, 2, p. 342–350.

37. KAUR, S., ZILMER, K., KAIRANE, C. et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br. J. Dermatol., 2008, 159, 6, p. 1364–1367.

38. KAUR, S., ZILMER, K., LEPING, V. et al. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol., 2011, 25, 11, p. 1328–1333.

39. KONDELKOVA, K., BORSKA, L., ANDRYS, C. et al. Selected inflammatory and metabolic markers in psoriatic patients treated with goeckerman therapy. Mediators Inflamm., 2015, 8. doi: 10.1155/2015/979526.979526.

40. LANDSBERG, L., ARONNE, L. J., BEILIN, L. J. et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment – a position paper of The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring), 2013, 21, 1, p. 8–24.

41. LI, W., HAN, J., CHOI, H. K., QURESHI, A. A. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am. J. Epidemiol., 2012, 175, 5, p. 402–413.

42. LITVINOVA, L., ATOCHIN, D., VASILENKO, M. et al. Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome. Diabetol. Metab. Syndr., 2014, 6, 1. doi: 10.1186/1758-5996-6-137.

43. LIU, S., MANSON, J. E. Dietary carbohydrates, physical inactivity, obesity, and the ‚metabolic syndrome‘ as predictors of coronary heart disease. Curr. Opin. Lipidol., 2001, 12, 4, p. 395–404.

44. LOPRINZI, P., WALKER, J. F. Combined association of physical activity and diet with C-reactive protein among smokers. J. Diabetes Metab. Disord., 2015, 14. doi: 10.1186/s40200-015-0181-y.

45. LOVE, T. J., QURESHI, A. A., KARLSON, E. W. et al. Prevalence of the Metabolic Syndrome in psoriasis: Results from the National Health and Nutrition Examination Survey, 2003-2006. Arch. Dermatol., 2011, 147, 4, p. 419–424.

46. MCDONALD, C. J., CALABRESI, P. Psoriasis and occlusive vascular disease. Br. J. Dermatol., 1978, 99, 5, p. 469–475.

47. MILČIĆ, D., JANKOVIĆ, S., VESIĆ, S. et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. An. Bras. Dermatol., 2017, 92, 1, p. 46–51.

48. MILLER, I. M., ELLERVIK, C., ZARCHI, K. et al. The association of metabolic syndrome and psoriasis: a population- and hospitalbased cross-sectional study. J. Eur. Acad. Dermatol. Venereol., 2015, 29, 3, p. 490–497.

49. MIZUNO, O., OKAMOTO, K., SAWADA, M. et al. Obesity and smoking: relationship with waist circumference and obesity-related disorders in men undergoing a health screening. J. Atheroscler. Thromb., 2005, 12, 4, p. 199–204.

50. MOUTZOURI, E., V. TSIMIHODIMOS, V., TSELEPIS, A. D. Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives. Curr. Pharm. Des., 2013, 19, 21, p. 3827–3840.

51. NALDI, L., CHATENOUD, L., LINDER, D. et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J. Invest. Dermatol., 2005, 125, 1, p. 61–67.

52. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002, 106, 25, p. 3143–3421.

53. NAVARRO, S. L., KANTOR, E. D., SONG, X. et al. Factors Associated with Multiple Biomarkers of Systemic Inflammation. Cancer. Epidemiol. Biomarkers Prev., 2016, 25, 3, p. 521–531.

54. OH, Y. J., LIM, H. K., CHOI, J. H. et al. Serum leptin and adiponectin levels in Korean patients with psoriasis. J. Korean Med. Sci., 2014, 29, 5, p. 729–734.

55. OWCZARCZYK SACZONEK, A., NOWICKI, R. The association between smoking and the prevalence of metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postępy Dermatol. Alergol., 2015, 32, 5, p. 331–336.

56. OWCZARCZYK-SACZONEK, A. B., NOWICKI, R. J., Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postep. Derm. Alergol., 2015, 32, 4, p. 290–295.

57. ÖZDEMIR, M., YÜKSEL, M., GÖKBEL, H. et al. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J. Dermatol., 2012, 39, 5, p. 443–448.

58. PAN, A., WANG, Y., TALAEI, M. et al. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol., 2015, 3, 12, p. 958–967.

59. PANKOVA, A., KRALIKOVA, E., FRASER, K. et al. No difference in hypertension prevalence in smokers, former smokers and non-smokers after adjusting for body mass index and age: a cross-sectional study from the Czech Republic, 2010. Tob. Induc. Dis., 2015, 13, 1, p. 24.

60. PARISI, R., SYMMONS, D. P., GRIFFITHS, C. E. et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol., 2013, 133, 2, p. 377–385.

61. PARK, H. S., OH, S. W., CHO, S. I. et al. The metabolic syndrome and associated lifestyle factors among South Korean adults. Int. J. Epidemiol., 2004, 33, 2, p. 328–336.

62. PEREIRA, R. R., AMLADI, S. T., VARTHAKAVI, P. K. A study of the prevalence of diabetes, insulin resistance, lipid abnormalities, and cardiovascular risk factors in patients with chronic plaque psoriasis. Indian. J. Dermatol., 2011, 56, 5, p. 520–526.

63. PUCCI, G., ALCIDI, R., TAP, L. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol. Res., 2017, 120, p. 34–42.

64. REAVEN, G., TSAO, P. S. Insulin resistance and compensatory hyperinsulinemia: The key player between cigarette smoking and cardio-vascular disease. J. Am. Coll. Cardiol., 2003, 41, 6, p. 1044–1047.

65. RICHER, V., ROUBILLE, C., FLEMING, P. et al. Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis Severity. J. Cutan. Med. Surg., 2016, 20, 3, p. 221–227.

66. ROMANÍ, J., CAIXÀS, A., CEPERUELO-MALLAFRÉ, V. et al. Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch. Dermatol. Res., 2013, 305, 2, p. 105–112.

67. SHIELS, M. S., KATKI, H. A., FREEDMAN, N. D. et al. Cigarette smoking and variations in systemic immune and inflammation markers. J. Natl. Cancer. Inst., 2014, 106, 11. doi: 10.1093/jnci/dju294.

68. SCHMITT, J., GOTTFRIED, W. The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis. Dermatology, 2005, 210, p. 194–199.

69. SOMMER, D. M., JENISCH, S., SUCHAN. M. et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res., 2006, 298, 7, p. 321–328.

70. SOVINOVÁ, H., CSÉMY, L. Užívání tabáku v České republice 2015. Státní zdravotní ústav, 2016.

71. STJERNHOLM, T., OMMEN, P., LANGKILDE, A. et al. Leptin-deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. Exp. Dermatol., 2016. doi: 10.1111/exd.13149.

72. TAKESHITA, J., GREWAL, S., LANGAN, S. M. et al. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol., 2017, 76, 3, p. 377–390.

73. TSELEPIS, A. D., PANAGIOTAKOS, D. B., PITSAVOS, C. et al. Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: the ATTICA Study. Atherosclerosis. 2009, 206, 1, p. 303–308.

74. VACHATOVA, S., BORSKA, L., ANDRYS, C., KREJSEK, J. et al. Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients. J. Immunol. Res., 2016. doi: 10.1155/2016/5380792.

75. VOSÁTKOVÁ, M., ČEŘOVSKÁ, J., ZAMRAZILOVÁ, H. et al. Prevalence of obesity and metabolic syndrome in adult population of selected regions of the Czech Republic. Relation to rating habits and smoking. Prague Medical Report, 2012, 113, 3, p. 206–216.

76. WOLK, K., SABAT, R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev. Endocr. Metab. Disord., 2016, 17, 3, p. 1–13.

77. WON, W. Y., LEE, C. U., CHAE, J. H. et al. Changes of plasma adiponectin levels after smoking cessation. Psychiatry Investig., 2014, 11, 2, p. 173–178.

78. ZHANG, X., WANG, H., TE-SHAO, H. et al. Frequent use of tobacco and alcohol in Chinese psoriasis patients. Int. J. Dermatol., 2002, 41, 10, p. 659–662.

79. ZINDANCI, I., ALBAYRAK, O., KAVALA, M. et al. Prevalence of metabolic syndrome in patients with psoriasis. ScientificWorldJournal, 2012, p. 312463–312463. DOI: 10.1100/2012/312463.

Labels

Dermatology & STDs Paediatric dermatology & STDs

The Molecular Biology of Cancer: the Basics for Clinical Practice

Frontal Fibrosing Alopecia

Article was published in

Czech-Slovak Dermatology

2017 Issue 6